Trials Sponsors Conditions Drugs Pricing

Conditions

Healthy

Keywords

Energy increaseEnergyHealthyanti-inflammatoryOpen-labelSalmon proteinNatural health productDietary supplement

Outcome Measures

Primary Outcomes (1)

The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
This questionnaire consists of a total of 30 questions that assess vitality and quality of life. The responses for these questions range from 1 to 7, where 1 indicates "never" or "not at all true" 4 indicates "sometimes" or "somewhat true" and 7 indicates "always" or "very true" depending on the item that is assessed by the question. 15 of the 30 questions are positively keyed in which a higher score indicates a better outcome and remaining 15 questions are negatively keyed where a lower score indicates a better outcome. The responses on the negatively keyed questions will be reversed prior to calculating the total score (i.e. a response of 1 will be considered as 7, 2 will be considered as 6, etc.). Total range will be 30-210, where a higher total score indicates a better outcome and a lower total score indicates a worse outcome.
Baseline (Day 0) to end-of-study (Day 128)

Secondary Outcomes (19)

Change From Baseline to Day 128 in Red Blood Cell (RBC) Count After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Volume (MCV) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin (MCH) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin Concentration (MCHC) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Baseline (Day 0) to end-of-study (Day 128)
Change From Baseline to Day 128 in Hematocrit After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Baseline (Day 0) to end-of-study (Day 128)

Other Outcomes (6)

The Incidence of Adverse Events Following a 128-day Supplementation
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Weight
Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Blood Pressure
Baseline (Day 0) to end-of-study (Day 128)
+3 more other outcomes

Study Arms (1)

Salmon Protein Hydrolysate (CollaGo®)

EXPERIMENTAL

Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.

Dietary Supplement: Salmon Protein Hydrolysate

Interventions

Salmon Protein HydrolysateDietary supplement

4g of salmon protein hydrolysate per serving.

Also known as: CollaGo®

Salmon Protein Hydrolysate (CollaGo®)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age30 Years - 60 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy male or female, 30-60 years of age
Female participant is not of child bearing potential, defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) or,

Sponsors & Collaborators

Hofseth Biocare ASA
Industrylead
KGK Science Inc.
Industrycollaborator

Study Sites (1)

KGK Science Inc.

London, Ontario, N6A 5R8, Canada

Results Point of Contact

Title: Dr. Mal Evans
Organization: KGK Science Inc.

Study Officials

David Crowley, MD
KGK Science Inc.
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restriction Type: OTHER
Restrictive Agreement: Yes

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 14, 2018

First Posted

May 24, 2018

Study Start

June 5, 2018

Actual (reported)

Primary Completion

A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (19)

Other Outcomes (6)

Study Arms (1)

Salmon Protein Hydrolysate (CollaGo®)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (19)

Other Outcomes (6)

Study Arms (1)

Salmon Protein Hydrolysate (CollaGo®)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations